Performance of Survival Prediction Tools in Patients With Gastrointestinal Stromal Tumors: A Systematic Review and Meta-Analysis.

J Surg OncolJun 18, 2026 (epub)
Clinical ResearchOncology (Medical)GastroenterologyOpen access

Alice Zhu, Chloe Wong, Neill K J Adhikari et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated survival prediction tools for adults with primary gastrointestinal stromal tumors (GISTs), analyzing 47 studies. The MSKCC nomogram was the most validated tool, demonstrating a pooled C-statistic of 0.78 for recurrence-free survival.

Key findings

  • The MSKCC nomogram had a pooled C-statistic of 0.78 for predicting recurrence-free survival.
  • A total of 47 studies were included, comprising 38 development and 9 validation studies.
  • External validation cohorts were used to assess the performance of the prognostic tools.

Why it matters

Accurate survival prediction in GIST patients is crucial for guiding treatment decisions and patient management. Understanding the effectiveness of various prognostic tools can enhance clinical outcomes.

Source

PubMed · PMID 42312566Free full text on PubMed Central

Published in J Surg Oncol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.